Ausgabe 1/2015
Inhalt (14 Artikel)
Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy
Michelle N. Messmer, Colleen S. Netherby, Debarati Banik, Scott I. Abrams
Novel N-amidinopiperidine-based proteasome inhibitor preserves dendritic cell functionality and rescues their Th1-polarizing capacity in Ramos-conditioned tumor environment
Urban Švajger, Martina Gobec, Aleš Obreza, Irena Mlinarič-Raščan
Identification of tumor-binding scFv derived from clonally related B cells in tumor and lymph node of a patient with breast cancer
Leah J. Novinger, Takamaru Ashikaga, David N. Krag
Evaluation of complement proteins as screening markers for colorectal cancer
Line Storm, Ib J. Christensen, Jens C. Jensenius, Hans J. Nielsen, Steffen Thiel
Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer
Hideki Kimura, Yukiko Matsui, Aki Ishikawa, Takahiro Nakajima, Mitsuru Yoshino, Yuichi Sakairi
Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
Balaji Balasa, Rui Yun, Nicole A. Belmar, Melvin Fox, Debra T. Chao, Michael D. Robbins, Gary C. Starling, Audie G. Rice
Cytokine production in peripheral blood cells of patients with differentiated thyroid cancer: elevated Th2/Th9 cytokine production before and reduced Th2 cytokine production after radioactive iodine therapy
Snezana Zivancevic Simonovic, Olgica Mihaljevic, Ivana Majstorovic, Predrag Djurdjevic, Irena Kostic, Olivera Milosevic Djordjevic, Ljiljana Mijatovic Teodorovic
Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies
Chiara Castelli, Licia Rivoltini, Monica Rodolfo, Marcella Tazzari, Cristina Belgiovine, Paola Allavena
Cancer stem cells: perspectives for therapeutic targeting
Cristina Maccalli, Ruggero De Maria
Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer
Zlatko Trajanoski, Cristina Maccalli, Daniele Mennonna, Giulia Casorati, Giorgio Parmiani, Paolo Dellabona
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
Luana Calabrò, Giovanni Luca Ceresoli, Alessandra di Pietro, Ornella Cutaia, Aldo Morra, Ramy Ibrahim, Michele Maio
Armed antibodies for cancer treatment: a promising tool in a changing era
Riccardo Danielli, Roberto Patuzzo, Pier Adelchi Ruffini, Andrea Maurichi, Leonardo Giovannoni, Giuliano Elia, Dario Neri, Mario Santinami
Overcoming the toxicity hurdles of genetically targeted T cells
Monica Casucci, Robert E. Hawkins, Gianpietro Dotti, Attilio Bondanza
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013
Michele Maio, Hugues Jean Marie Nicolay, Ornella Cutaia, Ester Fonsatti, Giorgio Parmiani